Yet, the role of CD146 expression in pediatric B-ALL remains to be defined; we propose that CD146 will be considered for subsequent studies in pediatric ALL to better define leukemic subtypes and whether to be a potential target for subsequent therapy like melanoma. Here, MCAM is linked to precursor B-cell acute lymphoblastic leukemia.